Semax research and evidence overview

Semax is a registered medicine in Russia with several hundred patients' worth of published clinical data behind it, mostly in stroke rehabilitation and chronic cerebrovascular disease. That is a real evidence base by peptide standards. It is also almost entirely Russian-language, largely open-label rather than double-blind, conducted in patient populations with diagnosed cerebrovascular disease, and unreplicated outside its country of origin. None of it addresses the use most buyers have in mind: cognitive enhancement in healthy people.

Post-stroke rehabilitation (n=110). Gusev and colleagues followed 110 patients after ischemic stroke (43 men, 67 women, mean age 58.0 ± 9.7 years), split into early (89 ± 9 days) and late (214 ± 22 days) rehabilitation groups, each subdivided into semax and non-semax subgroups. The semax regimen was 6,000 mcg/day for 10 days, twice, with a 20-day interval. Plasma BDNF rose and stayed elevated in the semax subgroups regardless of rehabilitation timing, and Barthel index recovery was faster and better, with a smaller effect on motor deficit (Zh Nevrol Psikhiatr, 2018). The design compares subgroups rather than randomised placebo arms, so expectancy effects on a functional scale cannot be excluded.

Chronic cerebrovascular insufficiency (n=187). An earlier study by Gusev, Skvortsova, and Chukanova assessed 187 patients across stages of cerebrovascular insufficiency using neurological and neuropsychological examination, dopplerography, EEG, and MRI. The authors reported clinical improvement, stabilisation of disease progression, a reduced rate of stroke and transient ischemic attacks, and good tolerability including in older patients (Zh Nevrol Psikhiatr, 2005). The abstract does not describe randomisation or blinding, and the composite of outcomes reported makes the effect size hard to pin down.

Semax is a synthetic fragment of ACTH(4-10) extended with a proline-glycine-proline tail, which blocks rapid enzymatic breakdown while removing corticotropic activity. Rodent and cell studies from Russian groups have examined neuroprotection in models of ischemia, effects on dopaminergic and serotonergic transmission, and induction of neurotrophic factors — BDNF and NGF in particular. The BDNF measurements in the 2018 stroke study are the human counterpart of that line of work, and they are the strongest objective signal in the clinical literature, since a blood biomarker is harder to bias than a rated functional scale.

A rise in plasma BDNF is still a mechanistic marker rather than a benefit. The same study found BDNF levels also rose with early rehabilitation alone.

• Trial populations were stroke and cerebrovascular-disease patients, not healthy adults seeking focus or memory gains.
• Reported designs are open or subgroup comparisons; double-blind placebo-controlled data are scarce.
• The studied route is intranasal at defined microgram doses; injectable research-grade products are a different exposure.
• Registration in Russia reflects that regulator's evidentiary standard; no FDA or EMA authorisation exists.

The fair summary is that Semax is a genuinely researched compound whose clinical evidence sits one tier below what Western regulators require, and whose marketed nootropic claims are extrapolations from stroke medicine.